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Summary
 
Recent evidence indicates that chronic autoimmune disease can result from breakdown of reg-
ulation and subsequent activation of self-reactive T cells. In many murine autoimmune disease
systems and in the Lewis rat, antigen-specific T cells utilizing the T cell receptor (TCR) V
 
b
 
8.2
gene segment play a major role. In the myelin basic protein–induced experimental autoim-
mune encephalomyelitis (EAE) model in H-2
 
u
 
 mice, we had shown that T cells recognizing a
peptide determinant within the framework 3 region of the V
 
b
 
8.2 chain have a critical role in
influencing the course of the disease. Here, we report experiments in another disease system,
collagen II (CII)–induced arthritis (CIA) in DBA/1LacJ (H-2
 
q
 
) mice, indicating a remarkably
parallel control circuit to that found for EAE. A critical role is played by CII-specific V
 
b
 
8.2-
bearing T cells in the CIA system, which we have confirmed. Animals treated with the super-
antigen SEB before CII administration are significantly protected from CIA. Next, we tested
the ability of peptides encompassing the entire V
 
b
 
8.2 chain to induce proliferative responses.
Only TCR peptide B5 (amino acids 76–101), a regulatory peptide in EAE, induced prolifera-
tion. B5 was then used to vaccinate DBA/1LacJ mice and was shown to reduce greatly the se-
verity and incidence of CIA as measured by joint inflammation or histology. Furthermore, sim-
ilar protection was found when B5 was administered after CII immunization. It was shown that
there is physiological induction of a proliferative response to B5 during CIA and that the deter-
minant within B5 is produced from a single chain TCR construct containing the entire V
 
b
 
8.2
chain. Finally, the regulation of CIA is discussed in the context of other experimental autoim-
mune diseases, especially EAE, with emphasis on what appear to be strikingly common mech-
anisms.
 
I
 
n recent years, a number of antigen-induced and sponta-
neous autoimmune diseases in susceptible strains of ro-
dents have been extensively studied. The accumulated evi-
dence, as well as clinical studies have led to the inference that
each of these autoimmune diseases is a representative model
for the human condition it most closely resembles. For ex-
ample, experimental autoimmune encephalomyelitis (EAE)
 
1
 
for multiple sclerosis, collagen II (CII)–induced arthritis (CIA)
for rheumatoid arthritis and diabetes in nonobese diabetic
(NOD) mice for insulin-dependent juvenile diabetes. A com-
mon theme found in studies with mice of the TCRV
 
b
 
b
 
haplotype but of many different H-2 haplotypes and in
Lewis rats is the key role of T cells using the V
 
b
 
8.2 gene
segment in primary recognition of autoantigens (1; see Dis-
cussion). These results suggest a common regulatory system
that controls potentially pathogenic self-reactive T cells. Ex-
perimental support for this idea comes from studies re-
ported here with CIA in H-2
 
q
 
 mice that appear to employ
similar regulation to that found for myelin basic protein
(MBP)-induced EAE in H-2
 
u
 
 mice.
Self-reactive T cells appear to be pivotal in the develop-
ment of several human autoimmune disorders, including
multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.
The plethora of observations linking a large number of
experimental autoimmune diseases in mice and rats with
the use of TCR encoded by the V
 
b
 
8.2 gene segment has
 
1
 
Abbreviations used in this paper:
 
 bCII, bovine collagen II; CIA, collagen II-
induced arthritis; CII, collagen II; EAE, experimental autoimmune en-
cephalomyelitis; EAN, experimental autoimmune neuritis; EAU, experi-
mental autoimmune uveoretinitis; IRBP, interphotoreceptor retinoid
binding protein; MBP, myelin basic protein; NOD, nonobese diabetic;
SEA, staphylococcal enterotoxin A; SEB, staphylococcal enterotoxin B;
S.I., stimulation index.
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prompted us to make a detailed comparison of initiation of
disease and regulation of potentially pathogenic self reactive
T cells in two well-defined murine experimental models,
namely CIA and EAE. It has previously been shown that T
cells using the TCR V
 
b
 
8.2 gene segment are required for
induction of EAE in H-2
 
u
 
 mice (2, 3). Antigen-induced
EAE, using MBP or peptide Ac1-9 of MBP as antigen, was
strongly inhibited with pretreatment by anti-V
 
b
 
8.2. We
have recently demonstrated in mice that the response to
self-MBP is controlled by potent regulatory T cell circuitry,
which is based on recognition of different determinants de-
rived from the TCR V
 
b
 
8.2 chain, in the context of class I
and class II MHC molecules (4–7). This TCR-based regula-
tion appears to be involved in maintaining peripheral tol-
erance to MBP, thus protecting mice from autoimmune
demyelination. Furthermore, TCR peptide-specific regula-
tory T cells appear to be responsible for natural recovery
from antigen-induced EAE in B10.PL mice (4–7).
CIA in rodents is an acute and severe experimental
model of autoimmune polyarthritis that develops following
immunization with heterologous type II collagen in adju-
vant (8–10); homologous CII appear to induce chronic and
progressive arthritis (7). Both MHC class II and non-MHC
genes play important roles in the susceptibility to disease
induction, with H-2
 
q
 
 and H-2
 
r
 
 being the most susceptible
MHC haplotypes (12). Although the relative contribution
of antibody and cellular mechanisms in disease is not yet
clear, there is evidence that T cells are critically involved in
the pathogenesis of CIA (13–16).
It has clearly been shown that the depletion of CD4
 
1
 
 T
cells in mice attenuates the incidence and delays the onset of
CIA (13). Similarly, CIA has been induced in rats by adop-
tive transfer of CD4
 
1
 
 T cells specific for CII (14, 15). It has
been suggested that in susceptible mouse strains expressing
either the complete TCR V
 
b
 
 gene repertoire (TCRV
 
b
 
b
 
)
or lacking part of the V
 
b
 
 gene segments (TCRV
 
b
 
a
 
), CIA is
mediated by CII-specific T cells using a limited set of TCR
V gene segments (17–21). These findings are in agreement
with the hypothesis that pathogenic T cells use a restricted
repertoire of V gene segments, as has previously been dem-
onstrated in the EAE system. It has been shown that T cells
specific for CII in DBA/1 mice as well as T cells infiltrating
the joints in B10.Q mice use a limited number of TCR V
genes (20, 21). The significant reduction in the incidence
of CIA in both DBA/1 as well as in B10.RIII mice treated
with anti-V
 
b
 
8 antibodies indicates that T cells expressing
V
 
b
 
8 TCR are important in the development of CIA (20–
23). Selective depletion of V
 
b
 
8-expressing T cells has been
shown to be as effective as the depletion of all 
 
ab
 
 T cells in
B10.R III mice (23). Here, using superantigenic stimula-
tion of T cells in vivo, we show that CII-specific T cells
expressing V
 
b
 
8.2 genes are crucial for the induction of CIA
in DBA/1LacJ mice. Our studies indicate that TCR V
 
b
 
8.2
chain–derived determinants are physiological targets for the
regulation of CIA and TCR–peptide-based regulation may
be critical for the maintenance of peripheral tolerance to
CII. These data also show that the same framework 3 re-
 
gion of the V
 
b
 
8.2 chain appears to be crucially involved in
regulation of both CIA and EAE.
 
Materials and Methods
 
Mice.
 
DBA/1LacJ mice (H-2
 
q
 
) were obtained from The
Jackson Laboratory (Bar Harbor, ME), and were bred at UCLA
under specific pathogen-free conditions. 8 to 12 wk-old male
mice were used for induction of arthritis.
 
Induction of CIA in DBA/1LacJ Mice.
 
Arthritis was induced in
DBA/1LacJ male mice after injection of 100 
 
m
 
g of heterologous
bovine CII. The bovine CII (Institut Jacques Bois, Reims, France)
was dissolved in 0.01 M acetic acid at 4
 
8
 
C overnight and emulsi-
fied in an equal volume of CFA (DIFCO, Detroit, MI). 3 wk af-
ter the primary injection, mice were again immunized with 100 
 
m
 
g
CII emulsified in IFA, intraperitoneally. A second injection with
collagen was necessary to induce severe and reproducible disease.
 
Peptide Synthesis.
 
Peptides were synthesized as described ear-
lier (5). The following are amino acid sequences of the TCR pep-
tides and are shown in the single letter amino acid code. B1 (1–30L),
EAAVTQSPRNKVAVTGGKVTLSCNQTNNHNL; B2 (21–
50), LSCNQTNNHNNMYWYRQDTGHGLRLIHYSY; B3
(41–70), HGLRLIHYSYGAGSTEKGDIPDGYKASRPS; B4 (61–
90), PDGYKASRPSQENFSLILELATPSQTSVYF; B5 (76–101),
LILELATPSQTSVYFCASGDAGGGYE.
 
T Cell Proliferation Assay.
 
Mice were immunized as above
with CII, or subcutaneously with 3–7 nmol of TCR peptide emul-
sified in CFA (DIFCO, Detroit, MI). Draining (para-aortic and
inguinal) lymph node cells were obtained 9–10 d later, and used
in antigen-induced proliferation assays. 5 
 
3
 
 10
 
5
 
 lymph node cells
were cultured in 0.2 ml of serum-free medium (HL-1; Ventrex,
Portland, ME or X-Vivo 10; BioWhittaker, Walkersville, MD)
medium alone, containing 2 mM glutamine, or with varying con-
centrations of collagen or specific TCR peptide in 96-well cul-
ture dishes for 4 d. Antigen-induced proliferation was assessed by
the incorporation of 1 
 
m
 
Ci of [
 
3
 
H]thymidine during the last 18 h
of culture. For splenic proliferation assays, erythrocytes were lysed
and the residual cells were plated as above in HL-1 or X-Vivo 10
medium at a density of 1 
 
3
 
 10
 
6
 
 cells in a total volume of 200 
 
m
 
l per
well in a 96-well plate with varying concentrations of antigens.
 
Flow Cytometry Analysis.
 
Antibodies were purified from hy-
bridoma supernatants by protein A chromatography. Anti-CD4–
PE (GK1.5) was acquired from Becton-Dickinson (Mountain View,
CA). Anti-V
 
b
 
8.2 (F23.2) (24) was used for TCR staining after
SEB treatment; The F23.2-producing hybridoma was provided
by Dr. M. Bevan (University of Washington, Seattle, WA). Anti-
bodies were used in PBS containing 1% fetal bovine serum. 1 
 
3
 
10
 
6
 
 cells were stained with 0.5 
 
m
 
g of antibody or biotinylated Ab
in a total volume of 50 
 
m
 
l at 4
 
8
 
C for 30 min. Cells were washed
twice with PBS and then resuspended in 50 
 
m
 
l of a 1:50 dilution
of either FITC-conjugated streptavidin or goat anti–mouse Ig–
FITC (Southern Biotechnology, Birmingham, AL). After 20 min
at 4
 
8
 
C, cells were washed, fixed with 1% paraformaldehyde in
PBS, and analyzed using a Becton-Dickinson cytofluorograph.
 
Anti-CII Antibody Response.
 
Mice were bled retro-orbitally
and serum samples were collected from individual mice and
stored at 
 
2
 
70
 
8
 
C until assay. A standard ELISA assay was used to
quantify the antibody response to CII. In brief, microtiter plates
were coated overnight with CII at a concentration of 10 
 
m
 
g/ml
in a total volume of 50 
 
m
 
l/well in PBS. After blocking remaining
protein-binding sites with BSA, diluted serum samples were in-
cubated and the amount of bound antibody determined by in- 
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cubation with goat anti–mouse IgG covalently coupled to alkaline
phosphatase (Southern Biotechnology, Birmingham, AL). A se-
rum pool collected from hyperimmune mice was used as a stan-
dard.
 
Results
 
Superantigen-induced Tolerance and Susceptibility to CIA.
 
As mentioned earlier, treatment of mice with antibodies
against the TCR V
 
b
 
8.2 gene segment has been shown to
reduce significantly the incidence of arthritis (21–23). Also,
the majority of T cells recognizing bovine CII (bCII) uti-
lize V
 
b
 
8.2 and V
 
a
 
11 gene segments in the DBA/1LacJ mouse
(21). In several experimental models, it has been demon-
strated that injection of mice with the superantigen, SEB,
results in an initial expansion of V
 
b
 
8.2 T cells followed by
clonal exhaustion and nonresponsiveness (25). We have
asked whether the disease-mediating response to bCII pre-
dominantly uses T cells expressing the V
 
b
 
8.2 gene seg-
ment; if so, clonal exhaustion or tolerance induction among
V
 
b
 
8.2 T cells after SEB challenge might result in protec-
tion from CIA. As shown in Table 1, DBA/1LacJ mice
given a single injection of SEB are significantly protected
from disease. In the SEB-treated group, 3 of 10 mice dis-
played mild arthritic symptoms (arthritic index, 1.1). In
contrast, within control groups, including the SEA-injected
group, 8 of 10 mice developed severe arthritis (arthritic in-
dex, 6.0). These data implicate V
 
b
 
8 T cells in mediating
CIA. Interestingly, mice injected with SEB 10 d after CII/
CFA injection were not protected (8 of 8) but rather devel-
oped more severe arthritis (arthritic index, 9.9) than those
in the control group (arthritic index, 5.3).
 
Immunogenicity of TCR–Peptides from the V
 
b
 
8.2 Chain in
DBA/1LacJ Mice.
 
To identify TCR determinants, we have
chemically synthesized five overlapping peptides (26–30
mers) encompassing the entire variable region of the TCR
V
 
b
 
8.2 chain. To characterize the immunogenicity of these
TCR peptides, mice were immunized subcutaneously with 7
nmol of individual peptides in CFA. 10 d later, prolifera-
tive responses in the draining lymph nodes were assayed
in response to an in vitro challenge. We found that only a
single peptide (B5) was able to elicit a lymph node prolifer-
ative response in DBA/1LacJ mice (Fig. 1). Interestingly,
T cells specific for the same TCR peptide, B5, have been
shown to regulate autoimmunity to MBP and are primed
naturally in B10.PL mice recovering from antigen-induced
EAE (4–7). Polyclonal T cell lines specific for B5 did not
proliferate in response to an adjacent overlapping peptide
B4 (data not shown).
 
Vaccination with TCR–Peptide-B5 Reduces Severity and In-
cidence of CIA.
 
In an attempt to influence the course of
CIA, DBA/1LacJ mice were vaccinated with 7 nmol of
B5/IFA twice, before challenge with bCII. Mice in the
control group were challenged with PBS/IFA or B4/IFA.
The effect of vaccination on the severity as well as on the
incidence of arthritis was examined in double-blind experi-
ments. We have performed three different experiments
with 5–8 mice in each group. A representative experiment
with B5 vaccination is shown in Fig. 2. In Table 2, data
pooled from three independent experiments are shown: 34
of 36 mice in the control groups (PBS/IFA and B4/IFA)
developed severe arthritis by 8–9 wk after CII immuniza-
tion, whereas only 6 of 18 mice in the B5-vaccinated group
 
Table 1.
 
Administration of SEB 10 d Before CII Challenge 
Protects Mice from CIA
 
Treatment group Incidence of disease Arthritis severity
PBS 8/10 6.0
SEB 3/10 1.1
SEA 8/9 5.7
Mice were injected with 50–100 
 
m
 
g of superantigen per animal 10 d
before the injection of CII/CFA for induction of arthritis. The percent-
age of CD4
 
1
 
, V
 
b
 
8.2
 
1
 
 T cells was analyzed by flow cytometry and
found to decrease significantly 48 h after SEB injection (7.9 
 
6
 
 1.5% in
controls versus 1.8 
 
6
 
 0.3% in SEB-treated group). Arthritis severity was
determined as in Fig. 2.
Figure 1. Immunogenicity of TCR–peptides from the Vb8.2 chain in
DBA/1LacJ mice. DBA/1LacJ mice were immunized with 7 nmol each
of the five overlapping TCR–peptides. 10 d later, draining lymph node
cells were assayed for proliferation in response to the immunizing peptide
at a concentration of 3.5 mM. [3H]thymidine incorporation was measured
by standard techniques. Individual responses in two mice are shown. The
amino acid sequences of the TCR peptides are given in Materials and
Methods. 
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displayed CIA. Importantly, B5-vaccinated mice contracted
less severe arthritis than mice in the control group (Table 2).
A majority of animals in the control group developed se-
vere arthritic symptoms in both front and hind limbs. In
contrast, arthritic symptoms were rarely detected in the
front limbs of mice vaccinated with B5. These data demon-
strate the efficacy of B5-specific T cells in modulating CIA
in DBA/1LacJ mice.
We have tested several variations of the B5 vaccination
protocol described in the legend for Fig. 2. Mice injected
only once with 14 nmol of B5 in IFA are not protected
from CIA. Furthermore, mice given only a single injection
of B5 even at a much higher concentration (50 nmol) are
not protected, but rather appear to have increased severity
of the disease (data not shown). Finally, we have asked
whether treatment with B5 after CII injection can protect
mice from CIA. In two independent experiments, DBA/
1LacJ mice challenged with B5 post-CII priming (days
 
1
 
10, 
 
1
 
20, 
 
1
 
30, Fig. 3 
 
A
 
; or days 
 
1
 
30, 
 
1
 
40, 
 
1
 
50, Fig.
3 
 
B
 
) show significant amelioration of disease. These data
clearly establish that B5-specific T cells are able to down
modulate CIA, even after CII-induced disease has been ini-
tiated.
Histologically, joints from untreated or control peptide
(B4)-treated animals were severely damaged by the rapidly
expanding synovial pannus. Mononuclear cell infiltration,
thickening of the synovial membrane, and bone marrow
erosion by osteoclasts, as well as cell exudate and polymor-
phonuclear cell accumulation in the synovial space were
present in the controls. In contrast, there were no signs of
an inflammatory process in 4 of 5 joints examined from
mice vaccinated with B5. Thus, lack of clinical disease in
B5-treated mice could be attributed to the absence of in-
flammation in the synovium (Fig. 4). Interestingly, the
anti-CII IgG response in groups treated with B5/IFA or
B4/IFA or PBS/IFA did not differ significantly, as shown
in Fig. 5. No significant difference in anti-CII titers was
seen between arthritic and non arthritic (B5-vaccinated)
mice, even though levels in individual mice varied consid-
erably.
Figure 2. Vaccination with TCR–peptide B5 reduces severity and in-
cidence of CIA. Groups of DBA/1LacJ mice (eight in each group) were
immunized subcutaneously with 100 mg of CII in one hind footpad. Dis-
ease was monitored in the three remaining limbs in a double-blind man-
ner by two individuals. Each limb was graded with a score of 1 through 4,
the maximum score being 12 for each mouse. The mean arthritis index
was determined by summation of the total score of each joint in each
group of mice and dividing by the total number of animals in each group.
For vaccination experiments, mice were injected with 7 nmol B5/IFA at
days 210 and 110 with respect to the primary CII injection (s). Control
mice were immunized with PBS/IFA (d).
 
Table 2.
 
Vaccination with TCR Peptide B5 Prevents CIA in 
DBA/1LacJ Mice
 
Treatment
CIA
Incidence Arthritis severity*
Control (PBS/IFA or B4/IFA) 34/36 9.8
B5/IFA 6/18 2.1
*Mean arthritic index was determined at 9 wk after CII immunization,
as described in the legend for Fig. 2. Mice were injected with B5/IFA
or B4/IFA or PBS/IFA at days 210 and 110 with respect to the pri-
mary CII injection, as described in the legend for Fig. 3.
Figure 3. DBA/1LacJ mice challenged with TCR peptide B5, after
CII immunization, are significantly protected from CIA. After immuniza-
tion with bovine CII, mice in each group (n 5 9) were challenged with
B5/IFA (h) or B4/IFA (r) on days 110, 120, 130 (A), or days 130,
140, 150 (B) relative to primary immunization with CII/CFA. These
immunizations were done as described in the legend for Fig. 2.1729 Kumar et al.
Induction of a Proliferative Response to B5 During CIA.
Although after peptide immunization (see Fig. 1), a prolif-
erative response was detected only to a single TCR–peptide,
B5, in DBA/1LacJ mice, it was important to determine
whether B5-specific T cells are activated physiologically
during the course of disease, in the absence of any chal-
lenge with the peptide itself. Mice were challenged with
CII for the induction of CIA. 35 d after primary immuni-
zation with CII, at which time mice had already developed
arthritic symptoms, peripheral T cells proliferated in vitro
in response to B5 (Fig. 6). Proliferative responses to any of
the other TCR peptides from the Vb8.2 chain were not
detected. Also, nonimmunized mice as well as mice immu-
nized with HEL showed no response to B5.
The dynamics of spontaneous activation of B5-specific T
cells was studied further by following spontaneous prolifer-
Figure 4. The infiltration of inflammatory cells into the synovium and
cartilage or bone erosion does not occur in B5-treated mice. Four mice
from each group treated with PBS/IFA, B4/IFA, or B5/IFA, were killed
12–14 wk after collagen II immunization. Hind limbs were formalin-
fixed, decalcified, embedded in paraffin, and stained in hematoxylin and
eosin. Tissue sections were examined and results are illustrated with a rep-
resentative example from each group.
Figure 5. In B5-treated mice, the IgG anti-collagen II response is not
inhibited. DBA/1LacJ mice were vaccinated with B5/IFA, B4/IFA, or
PBS/IFA as described in the legend for Fig. 2. Individual serum samples,
collected 8 wk after CII injection, were analyzed for the presence of anti-
CII IgG, using a standard ELISA assay. For the quantitation of IgG re-
sponses, a standard curve was generated using a hyperimmune antiserum
to CII. The values are represented in arbitrary units reflecting titers of the
anti-CII antibody in different groups of mice.
Figure 6. Physiological induction of a proliferative response to B5 dur-
ing CIA. DBA/1LacJ mice were immunized with CII for the induction
of CIA. 35 d later, splenic cells were assayed for proliferation in response
to a concentration (7 mM) of different TCR peptides, B1 and B5.
[3H]thymidine incorporation was measured by liquid scintillation count-
ing. There was no significant response to B5 in nonimmunized mice, nor
in mice challenged with HEL, 35 d after immunization. Individual re-
sponses of eight individual mice are shown.1730 T Cell Regulation of Collagen II–induced Arthritis
ation to B5 in lymph node and spleen cells isolated from
DBA/1LacJ mice (three mice in each group) 2, 10, 20, 30,
40, and 50 days after CII injection. In contrast with studies
in the EAE model, the proliferative response to B5 was rel-
atively lower (stimulation index [S.I.] of 2.5–3.0) until day
30. Interestingly, responsiveness to B5 continues to in-
crease even beyond day 50 (S.I. of 4–5). An indolent ex-
pansion of B5-reactive T cells could perhaps explain the
chronic nature of CIA, in that Treg are not able to expand
quickly enough to control the damage induced by CII-
reactive T cells.
T Cell Determinant(s) Within B5 Are Naturally Processed
and Presented. The existence of primed B5-specific T cells
in animals with CIA suggests that T cells specific for TCR
determinant(s) are physiologically primed. To examine fur-
ther immunodominance as well as the naturally processed
form of TCR determinants, soluble TCR-recombinant
single-chain TCRs containing appropriate Va and Vb
chains (26), produced in Escherichia coli and provided by Dr.
E. Sally Ward (Dallas, TX), were used to challenge DBA/
1LacJ mice. An in vitro recall response was tested with var-
ious Vb chain peptides. In parallel, TCR molecules con-
taining a Vb chain other than Vb8.2 were tested for speci-
ficity, to establish whether B5-reactive T cells could be
stimulated by TCR molecules containing the appropriate
Vb domain. As shown in Fig. 7, lymph node cells from
B5-primed mice gave good proliferative recall to the im-
munizing peptide B5, as well as to soluble recombinant
scTCR molecules containing the Vb8.2 chain (Vb8.2–Va4).
There was no proliferative recall to a different TCR pep-
tide (B3) or to scTCR molecules lacking a Vb8.2 chain,
such as Va4. These data clearly established that TCR de-
terminants within B5 are processed and presented follow-
ing CII injection.
Discussion
The studies reported in this paper demonstrate a remark-
ably parallel strategy in the regulation controlling bovine
CIA in H-2q mice and the previously examined MBP-
induced EAE in H-2u mice. In EAE, the major disease-
inducing, MBP-specific T cells are highly restricted in their
TCR V gene usage, predominantly using the Vb8.2 gene
segment. A variety of experiments point to potent regula-
tion by naturally primed CD4 T cells that recognize a
framework 3 region determinant of the Vb8.2 chain. Here,
we show that TCR peptide–specific T cells are implicated
in the physiological control of CII-reactive T cells, which
mediate autoimmune arthritis in DBA1/LacJ mice. Our
data support earlier studies (21–23) suggesting the in vivo
involvement of Vb8.2 T cells in CIA induced by CII, which
is accompanied by activation of T cells specific for a deter-
minant derived from the framework 3 region (peptide B5,
amino acids 76–101) of the Vb8.2 chain. Vaccination with
TCR peptide B5 before (Fig. 2) or after CII immunization
(Fig. 3) protects mice significantly from arthritis and pre-
vents inflammation in the synovia. With the use of recom-
binant scTCR protein containing the Vb8.2 chain, we were
able to determine that the framework 3 region determinant
is immunodominant and can be processed and presented
from the whole Vb8.2 chain.
Earlier studies from some laboratories (21–23), but not
from others (27) showed that CII-reactive T cell hybrido-
mas preferentially use the TCR Vb8.2 gene segment and
also that anti-Vb8.2 treatment resulted in a significant re-
duction in the incidence of arthritis in DBA/1LacJ mice.
Consistent with the role of Vb8.2 T cells, our data demon-
strate that mice treated with the superantigen, SEB, but not
with SEA, 10 d before antigenic challenge, are significantly
protected from CIA (Table 1), presumably by exhaustive
activation (25) of potential disease-causing T cell precur-
sors. SEB appears to exacerbate disease when given after
CII injection, perhaps by expanding/activating a previously
primed CII-reactive Vb8.2 T cell population. These stud-
ies further confirm the involvement of Vb8.2 T cells in
CII-induced arthritis in DBA/1LacJ mice.
It is a striking characteristic of experimentally induced
autoimmune diseases in mice (and the Lewis rat) bearing
the Vb8.2 gene that the autoimmune response appears to
focus on T cells utilizing the TCR Vb8.2 gene segment. In
the Lewis rat, MBP induced a remarkably homogeneous
response in which the induced T cells were specific for
peptides 68–88 and most used the TCR Vb8.2 gene seg-
ment (28). In H-2u mice, the response to MBP focuses on
the NH2-terminal peptide, Ac1-9, and again, the TCR
Vb8.2 gene segment is predominantly used (3, 4). In the
Lewis rat, experimental autoimmune neuritis (EAN), in-
duced by the myelin P-2 protein or peptides 53–78 of this
protein, and experimental autoimmune uveoretinitis (EAU)
induced by S antigen or interphotoreceptor retinoid bind-
ing protein (IRBP), are both characterized by the high fre-
quency of antigen-specific T cells using the Vb8.2 gene
segment in their TCRs (29, 30). EAU in B10.A mice is not
Figure 7. TCR determinant(s) within B5 are naturally processed and
presented. DBA/1LacJ mice were immunized with 7 nmol of B5 in CFA.
10 d later, draining lymph node cells were assayed for proliferation in
response to varying concentration of different antigens (3.5–14 mM).
[3H]thymidine incorporation, measured by standard techniques, at an op-
timum concentration, 7 mM, is shown. Responses in lymph node cells
pooled from two mice are shown. B5 and B3 are synthetic TCR pep-
tides, whereas Vb8.2–Va4 and Va4 are scTCR molecules containing
both V domains or only a single V domain, respectively.1731 Kumar et al.
as well characterized with regard to T cell usage, but there
is evidence that T cells using TCR Vb8.2 are also a major
component in this autoimmune disease (31). In BALB/c
mice, which are resistant to active EAE induction by MBP,
T cell clones specific for peptides 59–76 of mouse MBP
have been isolated that induce EAE upon transfer to naive
recipients (32). These clones are I-Ad–restricted and mainly
use the TCR Vb8.2 gene segment. Models of Sjogren’s
syndrome have been developed in several autoimmune-
prone strains (NZB 3 NZW)F1, MRL/lpr, and MRL(1/1)
and one strain (NFS/sld) not prone to autoimmunity (33,
34). The disease is characterized by lymphocytic infiltration
of the lacrimal glands and infiltrating T cells have been
identified bearing the TCR Vb8.2 gene segment. In NOD
mice, early induction of diabetes by a single injection of cyclo-
phosphamide is prevented by treatment with anti-Vb8.2
(35). In the autoimmunity-prone mouse strain, MRL/lpr,
there is amelioration of clinical autoimmunity by treatment
with anti-Vb8.2 or with SEB. Finally, with regard to CIA,
although some groups have failed to demonstrate an effect
of anti-Vb8.2 (27), in other studies a clear-cut inhibition of
CIA was shown. Clearly, our studies indicate a major in-
volvement of T cells utilizing Vb8.2 in CII-induced arthri-
tis in DBA/1LacJ mice. It is not yet known why autoantigen-
specific Vb8-expressing T cells play a major role in mediating
different experimental autoimmune diseases in rodents car-
rying Vb8 genes and also why Vb8-expressing T cells con-
stitute such a major proportion (10–30%) of the periph-
eral T cell repertoire.
For this reason, it is of interest to consider EAE induc-
tion in SJL (H-2s) and CIA in BUB (H-2q) mice, because
both these strains are of the TCRVba haplotype and lack
Vb8 genes. In SJL/J mice, MBP-induced EAE is character-
ized by T cells specific for peptides 89–101/As. There is
oligoclonality with predominant usage of the Vb4 or Vb17a
gene segment (36). In BUB mice, CII injection results in
inflammatory polyarthritis. TCR usage of T cells isolated
from arthritic joints appears to be limited to Vb3 and Vb10
gene segments (19). These results suggest that oligoclonal-
ity need not be restricted to the TCR Vb8 gene family and
may be characteristic of many autoimmune T cell responses.
It is significant that BUB mice, which lack the Vb8.2 gene,
contract severe CIA in contrast with the minimal response
in DBA/1LacJ mice in which Vb8.2-bearing T cells have
been greatly reduced by SEB treatment (Table 1) or by
anti-Vb8 treatment. Because genes coding for TCR Vb
chains used in the BUB mice are present in DBA/1LacJ
mice, it would appear that in Vb8.21 mice, a functional hi-
erarchy is established, perhaps during early development, in
which Vb3 or Vb10 TCR specific for CII are excluded.
It is remarkable that the B10.PL (H-2u) mouse and the
DBA/1LacJ (H-2q) mouse appear to use apparently similar
regulatory mechanisms in the physiological control of EAE
and CIA. In each case, a regulatory circuit is spontaneously
activated during the course of the disease after antigenic
challenge. T cells specific for the framework 3 region de-
terminant derived from the Vb8.2 chain are also spontane-
ously primed and involved in regulating EAE in the Lewis
rat model (37). It is interesting that despite the differences
in species, MHC haplotypes, background genes, and dis-
ease systems, T cells specific for the TCR determinants
within the same framework 3 region (B5 TCR–peptide,
amino acids 76–101), but not necessarily the same determi-
nant, become activated spontaneously. There could be at
least three relevant aspects to the broad use of B5, in partic-
ular, that could explain its predominant use in regulatory
circuitry. First, the likelihood is that B5 is efficiently pro-
cessed in a variety of mouse strains and becomes readily
available, leading to its immunodominance within the Vb8.2
TCR. Consistent with this, lymph node cells from both
B10.PL and DBA/1LacJ mice challenged with B5 respond
to recombinant single-chain TCR molecules containing the
entire Vb8.2 chain in recall proliferation assays. This indi-
cates that this TCR determinant can be processed and pre-
sented from the whole Vb8.2 chain. Second, the possibility
exists that B5 possesses one or more promiscuous determi-
nants, able to bind to various class II MHC molecules.
Third is the unusual feature of an apparent inability to in-
duce tolerance. Notably, we have not been able to induce
proliferative tolerance to this TCR peptide in neonatal
DBA/1LacJ mice or in the B10.PL mouse model (7; our
unpublished observations). In contrast, proliferative tolerance
to all other immunogenic TCR peptides or peptides from
any other antigen tested (from MBP, HEL, cyt C) could be
successfully induced after neonatal exposure.
The mechanism by which B5-specific Treg mediate pro-
tection from CIA is not yet clear. Preliminary data indicate
that B5 vaccination does not result in deletion of most
Vb8.2-expressing T cells in DBA/1LacJ mice. This is in
contrast with the mechanism suggested in BUB mice,
where immunization of mice with peptide 25–46 derived
from the TCR Vb10 chain resulted in deletion of most T
cells bearing TCR Vb10, presumably by induction of an
anti-Vb10 antibody response (38). Whether T cells specific
for the TCR Vb10–peptide are spontaneously primed and
are physiologically involved in regulation of CIA in BUB
mice remains unknown. Similarly, it is not known whether
TCR determinants on other Vb (and Va) chains are natu-
rally involved in such regulation (38, 39) or whether the
immune system focuses on T cells expressing the Vb8.2
chain to reestablish effective regulation of autoimmunity.
Currently, experiments are in progress to investigate fur-
ther whether CII-specific and Vb8.2-bearing T cells are de-
leted, or deviated to produce noninflammatory cytokines,
e.g., IL-4, after B5-induced regulation. Our preliminary
data indicate that regulatory mechanisms in EAE, as well as
in the CIA system, result in antigen-specific immune devi-
ation (Kumar, V., unpublished observations). CIA appears
to be mediated by CII-specific Th1-like cells, with anti-
gen-specific Th2 cells being protective.
With regard to regulation of EAE in B10.PL mice, regu-
latory T cells are specific for the peptide sequence derived
from the framework 3 region of the Vb8.2 chain, and does
not include the D–J region sequence, i.e., a sequence on all1732 T Cell Regulation of Collagen II–induced Arthritis
Vb8.2 TCRs is recognized. Nevertheless, the vast majority
of Vb8.2 cells are unaffected by vaccination with B5 or the
scTCR containing the Vb8.2 chain (4–7, Kumar, V., E.
Coulsell, B. Ober, G. Hubbard, E. Sercarz, and E. Sally
Ward, manuscript submitted for publication). In our pre-
liminary studies in the CIA model, only activated antigen-
specific T cells appear to be downregulated after vaccina-
tion of mice with B5, suggesting a similar mechanism to
that involved in the EAE model. These findings are consis-
tent with earlier indications that it is only activated T cells
which are subject to interaction with Treg (40). With rela-
tion to the treatment of chronic autoimmune diseases, it is
noteworthy that vaccination of mice with TCR peptide B5
as late as 30 d after CII immunization leads to a significant
inhibition in the incidence and severity of arthritis (Fig. 3).
It is likely that the common regulatory principles we have
described in the control of two distinct experimental au-
toimmune conditions define a generalized TCR centered
regulatory mechanism employed by the immune system.
This mechanism may be exploitable through specific thera-
peutic strategies in several human autoimmune diseases.
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